The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Anti-Obesity Therapeutics Market Research Report 2025

Global Anti-Obesity Therapeutics Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1431090

No of Pages : 98

Ask Your Query

Synopsis

Anti-obesity drugs are the drugs that help in reducing or controlling body mass, either by decreasing the craving or increasing the consumption of calories. Appetite control is achieved through the use of agonists for appetite suppressing pathways.

Due to the COVID-19 pandemic, the global Anti-Obesity Therapeutics market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Anti-Obesity Therapeutics market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Anti-Obesity Therapeutics landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

Geographically, North America captures the largest market share on account of increasing obese population. As per the historical trends, more than one-third of the U.S. population is obese. However, Asia Pacific is anticipated to grow at the fastest rate due to increasing demand for the drugs and awareness about the risk associated with obesity. According to WHO, 13.0% of the population were obese in 2014. In developing countries the rate of childhood obesity is increasing and has been 30.0% higher than that of developed countries.

This report focuses on Anti-Obesity Therapeutics volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Anti-Obesity Therapeutics market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

Global Anti-Obesity Therapeutics Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

  • Centrally Acting Anti-obesity Drugs
  • Peripherally Acting Anti-obesity Drugs

Segment by Application

  • Hospital Use
  • Clinic Use
  • Household
  • Other

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina, Colombia)

By Company

  • Bristol-Myers Squibb
  • Eisai Company
  • Flaxosithkline Plc.
  • Novo Nordisk
  • Alizyme
  • Boehringeringelheim Gmbh
  • Pfizer
  • Takeda Pharmaceutical
  • Rhythm Pharmaceuticals
  • Shionogi Usa
  • Vivus
  • Zafgen
  • Norgine Pharmaceuticals Ltd.
Index

1 Anti-Obesity Therapeutics Market Overview
1.1 Product Overview and Scope of Anti-Obesity Therapeutics
1.2 Anti-Obesity Therapeutics Segment by Type
1.2.1 Global Anti-Obesity Therapeutics Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Centrally Acting Anti-obesity Drugs
1.2.3 Peripherally Acting Anti-obesity Drugs
1.3 Anti-Obesity Therapeutics Segment by Application
1.3.1 Global Anti-Obesity Therapeutics Sales Comparison by Application: (2022-2028)
1.3.2 Hospital Use
1.3.3 Clinic Use
1.3.4 Household
1.3.5 Other
1.4 Global Anti-Obesity Therapeutics Market Size Estimates and Forecasts
1.4.1 Global Anti-Obesity Therapeutics Revenue 2017-2028
1.4.2 Global Anti-Obesity Therapeutics Sales 2017-2028
1.4.3 Anti-Obesity Therapeutics Market Size by Region: 2017 Versus 2021 Versus 2028
2 Anti-Obesity Therapeutics Market Competition by Manufacturers
2.1 Global Anti-Obesity Therapeutics Sales Market Share by Manufacturers (2017-2022)
2.2 Global Anti-Obesity Therapeutics Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Anti-Obesity Therapeutics Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Anti-Obesity Therapeutics Manufacturing Sites, Area Served, Product Type
2.5 Anti-Obesity Therapeutics Market Competitive Situation and Trends
2.5.1 Anti-Obesity Therapeutics Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Anti-Obesity Therapeutics Players Market Share by Revenue
2.5.3 Global Anti-Obesity Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-Obesity Therapeutics Retrospective Market Scenario by Region
3.1 Global Anti-Obesity Therapeutics Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Anti-Obesity Therapeutics Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Anti-Obesity Therapeutics Market Facts & Figures by Country
3.3.1 North America Anti-Obesity Therapeutics Sales by Country
3.3.2 North America Anti-Obesity Therapeutics Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Anti-Obesity Therapeutics Market Facts & Figures by Country
3.4.1 Europe Anti-Obesity Therapeutics Sales by Country
3.4.2 Europe Anti-Obesity Therapeutics Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Anti-Obesity Therapeutics Market Facts & Figures by Region
3.5.1 Asia Pacific Anti-Obesity Therapeutics Sales by Region
3.5.2 Asia Pacific Anti-Obesity Therapeutics Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Anti-Obesity Therapeutics Market Facts & Figures by Country
3.6.1 Latin America Anti-Obesity Therapeutics Sales by Country
3.6.2 Latin America Anti-Obesity Therapeutics Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Anti-Obesity Therapeutics Market Facts & Figures by Country
3.7.1 Middle East and Africa Anti-Obesity Therapeutics Sales by Country
3.7.2 Middle East and Africa Anti-Obesity Therapeutics Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Anti-Obesity Therapeutics Historic Market Analysis by Type
4.1 Global Anti-Obesity Therapeutics Sales Market Share by Type (2017-2022)
4.2 Global Anti-Obesity Therapeutics Revenue Market Share by Type (2017-2022)
4.3 Global Anti-Obesity Therapeutics Price by Type (2017-2022)
5 Global Anti-Obesity Therapeutics Historic Market Analysis by Application
5.1 Global Anti-Obesity Therapeutics Sales Market Share by Application (2017-2022)
5.2 Global Anti-Obesity Therapeutics Revenue Market Share by Application (2017-2022)
5.3 Global Anti-Obesity Therapeutics Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Bristol-Myers Squibb
6.1.1 Bristol-Myers Squibb Corporation Information
6.1.2 Bristol-Myers Squibb Description and Business Overview
6.1.3 Bristol-Myers Squibb Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Bristol-Myers Squibb Anti-Obesity Therapeutics Product Portfolio
6.1.5 Bristol-Myers Squibb Recent Developments/Updates
6.2 Eisai Company
6.2.1 Eisai Company Corporation Information
6.2.2 Eisai Company Description and Business Overview
6.2.3 Eisai Company Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Eisai Company Anti-Obesity Therapeutics Product Portfolio
6.2.5 Eisai Company Recent Developments/Updates
6.3 FlaxoSithKline plc.
6.3.1 FlaxoSithKline plc. Corporation Information
6.3.2 FlaxoSithKline plc. Description and Business Overview
6.3.3 FlaxoSithKline plc. Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.3.4 FlaxoSithKline plc. Anti-Obesity Therapeutics Product Portfolio
6.3.5 FlaxoSithKline plc. Recent Developments/Updates
6.4 Novo Nordisk
6.4.1 Novo Nordisk Corporation Information
6.4.2 Novo Nordisk Description and Business Overview
6.4.3 Novo Nordisk Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Novo Nordisk Anti-Obesity Therapeutics Product Portfolio
6.4.5 Novo Nordisk Recent Developments/Updates
6.5 Alizyme
6.5.1 Alizyme Corporation Information
6.5.2 Alizyme Description and Business Overview
6.5.3 Alizyme Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Alizyme Anti-Obesity Therapeutics Product Portfolio
6.5.5 Alizyme Recent Developments/Updates
6.6 BoehringerIngelheim GmbH
6.6.1 BoehringerIngelheim GmbH Corporation Information
6.6.2 BoehringerIngelheim GmbH Description and Business Overview
6.6.3 BoehringerIngelheim GmbH Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.6.4 BoehringerIngelheim GmbH Anti-Obesity Therapeutics Product Portfolio
6.6.5 BoehringerIngelheim GmbH Recent Developments/Updates
6.7 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Pfizer Anti-Obesity Therapeutics Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Takeda Pharmaceutical
6.8.1 Takeda Pharmaceutical Corporation Information
6.8.2 Takeda Pharmaceutical Description and Business Overview
6.8.3 Takeda Pharmaceutical Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Takeda Pharmaceutical Anti-Obesity Therapeutics Product Portfolio
6.8.5 Takeda Pharmaceutical Recent Developments/Updates
6.9 Rhythm Pharmaceuticals
6.9.1 Rhythm Pharmaceuticals Corporation Information
6.9.2 Rhythm Pharmaceuticals Description and Business Overview
6.9.3 Rhythm Pharmaceuticals Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Rhythm Pharmaceuticals Anti-Obesity Therapeutics Product Portfolio
6.9.5 Rhythm Pharmaceuticals Recent Developments/Updates
6.10 Shionogi USA
6.10.1 Shionogi USA Corporation Information
6.10.2 Shionogi USA Description and Business Overview
6.10.3 Shionogi USA Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Shionogi USA Anti-Obesity Therapeutics Product Portfolio
6.10.5 Shionogi USA Recent Developments/Updates
6.11 Vivus
6.11.1 Vivus Corporation Information
6.11.2 Vivus Anti-Obesity Therapeutics Description and Business Overview
6.11.3 Vivus Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Vivus Anti-Obesity Therapeutics Product Portfolio
6.11.5 Vivus Recent Developments/Updates
6.12 Zafgen
6.12.1 Zafgen Corporation Information
6.12.2 Zafgen Anti-Obesity Therapeutics Description and Business Overview
6.12.3 Zafgen Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Zafgen Anti-Obesity Therapeutics Product Portfolio
6.12.5 Zafgen Recent Developments/Updates
6.13 Norgine Pharmaceuticals Ltd.
6.13.1 Norgine Pharmaceuticals Ltd. Corporation Information
6.13.2 Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Description and Business Overview
6.13.3 Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Product Portfolio
6.13.5 Norgine Pharmaceuticals Ltd. Recent Developments/Updates
7 Anti-Obesity Therapeutics Manufacturing Cost Analysis
7.1 Anti-Obesity Therapeutics Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Anti-Obesity Therapeutics
7.4 Anti-Obesity Therapeutics Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Anti-Obesity Therapeutics Distributors List
8.3 Anti-Obesity Therapeutics Customers
9 Anti-Obesity Therapeutics Market Dynamics
9.1 Anti-Obesity Therapeutics Industry Trends
9.2 Anti-Obesity Therapeutics Market Drivers
9.3 Anti-Obesity Therapeutics Market Challenges
9.4 Anti-Obesity Therapeutics Market Restraints
10 Global Market Forecast
10.1 Anti-Obesity Therapeutics Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Anti-Obesity Therapeutics by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Anti-Obesity Therapeutics by Type (2023-2028)
10.2 Anti-Obesity Therapeutics Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Anti-Obesity Therapeutics by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Anti-Obesity Therapeutics by Application (2023-2028)
10.3 Anti-Obesity Therapeutics Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Anti-Obesity Therapeutics by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Anti-Obesity Therapeutics by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Anti-Obesity Therapeutics Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Anti-Obesity Therapeutics Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Anti-Obesity Therapeutics Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Anti-Obesity Therapeutics Market Competitive Situation by Manufacturers in 2021
Table 5. Global Anti-Obesity Therapeutics Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Anti-Obesity Therapeutics Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Anti-Obesity Therapeutics Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Anti-Obesity Therapeutics Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Anti-Obesity Therapeutics Average Price (USD/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Anti-Obesity Therapeutics Manufacturing Sites and Area Served
Table 11. Manufacturers Anti-Obesity Therapeutics Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Anti-Obesity Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Obesity Therapeutics as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Anti-Obesity Therapeutics Sales by Region (2017-2022) & (K Units)
Table 16. Global Anti-Obesity Therapeutics Sales Market Share by Region (2017-2022)
Table 17. Global Anti-Obesity Therapeutics Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Anti-Obesity Therapeutics Revenue Market Share by Region (2017-2022)
Table 19. North America Anti-Obesity Therapeutics Sales by Country (2017-2022) & (K Units)
Table 20. North America Anti-Obesity Therapeutics Sales Market Share by Country (2017-2022)
Table 21. North America Anti-Obesity Therapeutics Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Anti-Obesity Therapeutics Revenue Market Share by Country (2017-2022)
Table 23. Europe Anti-Obesity Therapeutics Sales by Country (2017-2022) & (K Units)
Table 24. Europe Anti-Obesity Therapeutics Sales Market Share by Country (2017-2022)
Table 25. Europe Anti-Obesity Therapeutics Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Anti-Obesity Therapeutics Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Anti-Obesity Therapeutics Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Anti-Obesity Therapeutics Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Anti-Obesity Therapeutics Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Anti-Obesity Therapeutics Revenue Market Share by Region (2017-2022)
Table 31. Latin America Anti-Obesity Therapeutics Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Anti-Obesity Therapeutics Sales Market Share by Country (2017-2022)
Table 33. Latin America Anti-Obesity Therapeutics Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Anti-Obesity Therapeutics Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Anti-Obesity Therapeutics Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Anti-Obesity Therapeutics Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Anti-Obesity Therapeutics Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Anti-Obesity Therapeutics Revenue Market Share by Country (2017-2022)
Table 39. Global Anti-Obesity Therapeutics Sales by Type (2017-2022) & (K Units)
Table 40. Global Anti-Obesity Therapeutics Sales Market Share by Type (2017-2022)
Table 41. Global Anti-Obesity Therapeutics Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Anti-Obesity Therapeutics Revenue Share by Type (2017-2022)
Table 43. Global Anti-Obesity Therapeutics Price by Type (2017-2022) & (USD/Unit)
Table 44. Global Anti-Obesity Therapeutics Sales (K Units) by Application (2017-2022)
Table 45. Global Anti-Obesity Therapeutics Sales Market Share by Application (2017-2022)
Table 46. Global Anti-Obesity Therapeutics Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Anti-Obesity Therapeutics Revenue Share by Application (2017-2022)
Table 48. Global Anti-Obesity Therapeutics Price by Application (2017-2022) & (USD/Unit)
Table 49. Bristol-Myers Squibb Corporation Information
Table 50. Bristol-Myers Squibb Description and Business Overview
Table 51. Bristol-Myers Squibb Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 52. Bristol-Myers Squibb Anti-Obesity Therapeutics Product
Table 53. Bristol-Myers Squibb Recent Developments/Updates
Table 54. Eisai Company Corporation Information
Table 55. Eisai Company Description and Business Overview
Table 56. Eisai Company Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 57. Eisai Company Anti-Obesity Therapeutics Product
Table 58. Eisai Company Recent Developments/Updates
Table 59. FlaxoSithKline plc. Corporation Information
Table 60. FlaxoSithKline plc. Description and Business Overview
Table 61. FlaxoSithKline plc. Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 62. FlaxoSithKline plc. Anti-Obesity Therapeutics Product
Table 63. FlaxoSithKline plc. Recent Developments/Updates
Table 64. Novo Nordisk Corporation Information
Table 65. Novo Nordisk Description and Business Overview
Table 66. Novo Nordisk Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 67. Novo Nordisk Anti-Obesity Therapeutics Product
Table 68. Novo Nordisk Recent Developments/Updates
Table 69. Alizyme Corporation Information
Table 70. Alizyme Description and Business Overview
Table 71. Alizyme Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 72. Alizyme Anti-Obesity Therapeutics Product
Table 73. Alizyme Recent Developments/Updates
Table 74. BoehringerIngelheim GmbH Corporation Information
Table 75. BoehringerIngelheim GmbH Description and Business Overview
Table 76. BoehringerIngelheim GmbH Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 77. BoehringerIngelheim GmbH Anti-Obesity Therapeutics Product
Table 78. BoehringerIngelheim GmbH Recent Developments/Updates
Table 79. Pfizer Corporation Information
Table 80. Pfizer Description and Business Overview
Table 81. Pfizer Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 82. Pfizer Anti-Obesity Therapeutics Product
Table 83. Pfizer Recent Developments/Updates
Table 84. Takeda Pharmaceutical Corporation Information
Table 85. Takeda Pharmaceutical Description and Business Overview
Table 86. Takeda Pharmaceutical Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 87. Takeda Pharmaceutical Anti-Obesity Therapeutics Product
Table 88. Takeda Pharmaceutical Recent Developments/Updates
Table 89. Rhythm Pharmaceuticals Corporation Information
Table 90. Rhythm Pharmaceuticals Description and Business Overview
Table 91. Rhythm Pharmaceuticals Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 92. Rhythm Pharmaceuticals Anti-Obesity Therapeutics Product
Table 93. Rhythm Pharmaceuticals Recent Developments/Updates
Table 94. Shionogi USA Corporation Information
Table 95. Shionogi USA Description and Business Overview
Table 96. Shionogi USA Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 97. Shionogi USA Anti-Obesity Therapeutics Product
Table 98. Shionogi USA Recent Developments/Updates
Table 99. Vivus Corporation Information
Table 100. Vivus Description and Business Overview
Table 101. Vivus Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 102. Vivus Anti-Obesity Therapeutics Product
Table 103. Vivus Recent Developments/Updates
Table 104. Zafgen Corporation Information
Table 105. Zafgen Description and Business Overview
Table 106. Zafgen Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 107. Zafgen Anti-Obesity Therapeutics Product
Table 108. Zafgen Recent Developments/Updates
Table 109. Norgine Pharmaceuticals Ltd. Corporation Information
Table 110. Norgine Pharmaceuticals Ltd. Description and Business Overview
Table 111. Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 112. Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Product
Table 113. Norgine Pharmaceuticals Ltd. Recent Developments/Updates
Table 114. Production Base and Market Concentration Rate of Raw Material
Table 115. Key Suppliers of Raw Materials
Table 116. Anti-Obesity Therapeutics Distributors List
Table 117. Anti-Obesity Therapeutics Customers List
Table 118. Anti-Obesity Therapeutics Market Trends
Table 119. Anti-Obesity Therapeutics Market Drivers
Table 120. Anti-Obesity Therapeutics Market Challenges
Table 121. Anti-Obesity Therapeutics Market Restraints
Table 122. Global Anti-Obesity Therapeutics Sales Forecast by Type (2023-2028) & (K Units)
Table 123. Global Anti-Obesity Therapeutics Sales Market Share Forecast by Type (2023-2028)
Table 124. Global Anti-Obesity Therapeutics Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 125. Global Anti-Obesity Therapeutics Revenue Market Share Forecast by Type (2023-2028)
Table 126. Global Anti-Obesity Therapeutics Sales Forecast by Application (2023-2028) & (K Units)
Table 127. Global Anti-Obesity Therapeutics Sales Market Share Forecast by Application (2023-2028)
Table 128. Global Anti-Obesity Therapeutics Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 129. Global Anti-Obesity Therapeutics Revenue Market Share Forecast by Application (2023-2028)
Table 130. Global Anti-Obesity Therapeutics Sales Forecast by Region (2023-2028) & (K Units)
Table 131. Global Anti-Obesity Therapeutics Sales Market Share Forecast by Region (2023-2028)
Table 132. Global Anti-Obesity Therapeutics Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 133. Global Anti-Obesity Therapeutics Revenue Market Share Forecast by Region (2023-2028)
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Anti-Obesity Therapeutics
Figure 2. Global Anti-Obesity Therapeutics Market Share by Type in 2021 & 2028
Figure 3. Centrally Acting Anti-obesity Drugs Product Picture
Figure 4. Peripherally Acting Anti-obesity Drugs Product Picture
Figure 5. Global Anti-Obesity Therapeutics Market Share by Application in 2021 & 2028
Figure 6. Hospital Use
Figure 7. Clinic Use
Figure 8. Household
Figure 9. Other
Figure 10. Global Anti-Obesity Therapeutics Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Anti-Obesity Therapeutics Market Size (2017-2028) & (US$ Million)
Figure 12. Global Anti-Obesity Therapeutics Sales (2017-2028) & (K Units)
Figure 13. Anti-Obesity Therapeutics Sales Share by Manufacturers in 2021
Figure 14. Global Anti-Obesity Therapeutics Revenue Share by Manufacturers in 2021
Figure 15. The Global 5 and 10 Largest Anti-Obesity Therapeutics Players: Market Share by Revenue in 2021
Figure 16. Anti-Obesity Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 17. Global Anti-Obesity Therapeutics Sales Market Share by Region (2017-2022)
Figure 18. Global Anti-Obesity Therapeutics Sales Market Share by Region in 2021
Figure 19. Global Anti-Obesity Therapeutics Revenue Market Share by Region (2017-2022)
Figure 20. Global Anti-Obesity Therapeutics Revenue Market Share by Region in 2021
Figure 21. U.S. Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. Canada Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. Germany Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. France Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. U.K. Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Italy Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Russia Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. China Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. Japan Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. South Korea Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. India Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Australia Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Taiwan Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Indonesia Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Thailand Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Malaysia Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Philippines Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Vietnam Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Mexico Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Brazil Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Argentina Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Turkey Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Saudi Arabia Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. U.A.E Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 45. Sales Market Share of Anti-Obesity Therapeutics by Type (2017-2022)
Figure 46. Manufacturing Cost Structure of Anti-Obesity Therapeutics
Figure 47. Manufacturing Process Analysis of Anti-Obesity Therapeutics
Figure 48. Anti-Obesity Therapeutics Industrial Chain Analysis
Figure 49. Channels of Distribution
Figure 50. Distributors Profiles
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock